Eylea's newest regulatory win will help Regeneron steel itself as brolucizumab threatens the company's grip on the wet aged-related macular degeneration (AMD) market. RELATED: Novartis' speedy brolucizumab review tees up battle with Eylea, Lucentis In April, the FDA granted priority review to brolucizumab for treatment of AMD after interim data from two phase 3 trials showed the drug stacked up well against Eylea in its primary endpoints and even bested the blockbuster in several secondary endpoints, including reducing retinal fluid and central subfield thickness. Novartis is expecting a decision from the FDA by October and is building its sales division to capture the peak $1.68 billion analysts have predicted.